Boehringer Ingelheim and Re-Vana Partner to Develop First-in-Class Ocular Therapies
German pharmaceutical giant Boehringer Ingelheim (BI) today announced a strategic collaboration and licensing agreement with...
Boehringer Ingelheim
Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025
Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group...
Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion
German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology...
Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema
German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...
Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH
Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise...
Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke
Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...
Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...
Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis
Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...
Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply
German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China)...
Boehringer Ingelheim Partners with Tessellate Bio on ALT Cancer Therapies
Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global...
Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases
Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc....
Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins
Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer...
Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud
German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of...
Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s...
Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents
The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...
Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment
Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...
Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931
German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...
Boehringer Ingelheim’s Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC
Germany-based Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has accepted its...
Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study
German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...